No undisputable evidence for bevacizumab-induced ILD as of Oct, 2014

Last update : 05/01/2020
I - Interstitial/parenchymal lung disease
II - Pulmonary edema - Acute lung injury - ARDS
III - Pulmonary/alveolar hemorrhage
IV - Airway involvement
V - Pleural and/or pericardial involvement
VI - Pulmonary vasculopathies
VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
X - Systemic/Distant conditions, syndromes and reactions
XI - Miscellaneous
XII - Cardiovascular involvement / toxicity
XVI - Imaging